Jura Health and Samba Scientific partner to improve genomic testing access to underserved populations
Jura Health and Samba Scientific join forces to enhance genomic testing accessibility for underserved populations, driving health equity.
CMC Pharma Subcontracted for Nerve Agent Countermeasure Development Program by Battelle and the U.S. Department of Defense
Discover how CMC Pharma is advancing nerve agent defense solutions with its growing portfolio of innovative medical countermeasures.
Broad Clinical Labs and Genomes2Veterans Partner on Veterans Affairs’ Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
Broad Clinical Labs and Genomes2Veterans join forces to advance prostate cancer genetic risk research and equitable screening for veterans.
AGC Biologics Seattle Achieves Approval for all 2024 Biologics License Applications from U.S. Food and Drug Administration, Concluding Pre-License Inspection
AGC Biologics’ Seattle facility achieves approval for three BLAs, showcasing excellence in biopharmaceutical manufacturing and innovation.
Adare Pharma, Laxxon Partner to Advance 3D Printed Oral Dosage Forms
Adare Pharma and Laxxon team up to innovate 3D-printed oral dosage forms, advancing precision medicine and patient care solutions.
Circular Genomics Announces Launch of MindLight™, the First SSRI Antidepressant Response Test Using Brain-Derived Biomarkers
Discover MindLight by Circular Genomics, the innovative SSRI response test transforming personalized antidepressant treatment.
TwinStrand Biosciences and Exact Sciences Announce Exclusive License Agreement for Duplex Sequencing Technology
SEATTLE, April 24, 2024 /PRNewswire/ — TwinStrand Biosciences®, the pioneer in Duplex Sequencing technology, which delivers accurate insights to researchers in applications ranging from genetic toxicology to residual cancer detection announces the successful acceptance of the standard project submission form (SPSF) by the Organization for Economic Cooperation and Development (OECD). This significant milestone will accelerate commencement of the global regulatory acceptance process for error-corrected Next Generation Sequencing (ecNGS) for mutagenesis testing.
Ultrasensitive Circulating Tumor DNA Improves NSCLC Detection
JUN 13, 2024 Ultrasensitive circulating tumor DNA (ctDNA) detection appears to improve the clinical sensitivity of minimal residual disease (MRD) at key landmarks in early stage non-small cell lung cancer (NSCLC), researchers reported at the 2024 ASCO Annual Meeting. “PhasED-Seq detected MRD at levels below one ppm and was associated with significantly better outcomes, revealing potential benefits […]
Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of work with VAR2 Pharmaceuticals on the production of the company’s two antibody candidates targeting cancer-specific carbohydrate structures for cancer treatment.
AGC Biologics Doubles Single-Use Bioreactor Capacity with Expansion at Denmark Site
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of work with VAR2 Pharmaceuticals on the production of the company’s two antibody candidates targeting cancer-specific carbohydrate structures for cancer treatment.
